Literature DB >> 25724817

Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?

Nicola Scichilone1, Alida Benfante2, Marialuisa Bocchino3, Fulvio Braido4, Pierluigi Paggiaro5, Alberto Papi6, Pierachille Santus7, Alessandro Sanduzzi3.   

Abstract

Inhalation is the preferred route of drug administration in chronic respiratory diseases because it optimises delivery of the active compounds to the targeted site and minimises side effects from systemic distribution. The choice of a device should be made after careful evaluation of the patient's clinical condition (degree of airway obstruction, comorbidities), as well as their ability to coordinate the inhalation manoeuvre and to generate sufficient inspiratory flow. These patient factors must be aligned with the specific advantages and limitations of each inhaler when making this important choice. Finally, adherence to treatment is not the responsibility of the patient alone, but should be shared also by clinicians. Clinicians have access to a wide selection of pressurised metered dose inhalers (pMDIs) and dry powder inhalers (DPIs) that can be used effectively when matched to the needs of individual patients; this should be perceived as an opportunity rather than a limitation.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adherence; Asthma; COPD; Inhaler

Mesh:

Substances:

Year:  2015        PMID: 25724817     DOI: 10.1016/j.pupt.2015.02.006

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  14 in total

1.  The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease.

Authors:  Dave Singh; Arjun Ravi; Katie Kane; Tess Schmalbach; David L Hava
Journal:  Br J Clin Pharmacol       Date:  2018-07-10       Impact factor: 4.335

2.  Real-world asthma management with inhaler devices in Switzerland-results of the asthma survey.

Authors:  Christian F Clarenbach; Laurent P Nicod; Malcolm Kohler
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 3.  Pharmacological Management of Elderly Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?

Authors:  Daniela Castiglia; Salvatore Battaglia; Alida Benfante; Claudio Sorino; Nicola Scichilone
Journal:  Drugs Aging       Date:  2016-06       Impact factor: 3.923

4.  Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Albuterol (Salbuterol) Multi-dose Dry-Powder Inhaler and ProAir(®) Hydrofluoroalkane for the Treatment of Persistent Asthma: Results of Two Randomized Double-Blind Studies.

Authors:  Edward M Kerwin; Herminia Taveras; Harald Iverson; Denise Wayne; Tushar Shah; Mark S Lepore; David S Miller
Journal:  Clin Drug Investig       Date:  2016-01       Impact factor: 2.859

Review 5.  Effects of aclidinium on determinants of COPD severity: symptoms and quality of life.

Authors:  Marco Contoli; Paolo Solidoro; Fabiano Di Marco; Nicola Scichilone; Angelo Corsico; Fulvio Braido; Pierachille Santus
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-12-05

Review 6.  Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes.

Authors:  Omar Sharif Usmani; Federico Lavorini; Jonathan Marshall; William Christopher Nigel Dunlop; Louise Heron; Emily Farrington; Richard Dekhuijzen
Journal:  Respir Res       Date:  2018-01-16

Review 7.  The evidence on tiotropium bromide in asthma: from the rationale to the bedside.

Authors:  Dejan Radovanovic; Pierachille Santus; Francesco Blasi; Marco Mantero
Journal:  Multidiscip Respir Med       Date:  2017-05-04

Review 8.  Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease.

Authors:  Pierachille Santus; Dejan Radovanovic; Andrea Cristiano; Vincenzo Valenti; Maurizio Rizzi
Journal:  Drug Des Devel Ther       Date:  2017-11-15       Impact factor: 4.162

9.  Efficacy and usability of a novel nebulizer targeting both upper and lower airways.

Authors:  Daniela Posa; Antonio Pizzulli; Petra Wagner; Serena Perna; Stephanie Hofmaier; Paolo Maria Matricardi; Susanne Lau
Journal:  Ital J Pediatr       Date:  2017-09-29       Impact factor: 2.638

Review 10.  Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes.

Authors:  Jens Markus Borghardt; Charlotte Kloft; Ashish Sharma
Journal:  Can Respir J       Date:  2018-06-19       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.